Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$194.69 - $268.46 $66.9 Million - $92.3 Million
-343,690 Reduced 83.09%
69,950 $18.7 Million
Q2 2022

Aug 15, 2022

BUY
$187.54 - $223.02 $2.25 Million - $2.67 Million
11,980 Added 2.98%
413,640 $84.4 Million
Q1 2022

May 16, 2022

SELL
$193.77 - $244.14 $10 Million - $12.6 Million
-51,740 Reduced 11.41%
401,660 $84.6 Million
Q4 2021

Feb 14, 2022

SELL
$223.92 - $287.77 $3.01 Million - $3.86 Million
-13,430 Reduced 2.88%
453,400 $109 Million
Q3 2021

Nov 15, 2021

BUY
$282.99 - $369.05 $36.1 Million - $47.1 Million
127,530 Added 37.59%
466,830 $132 Million
Q2 2021

Aug 16, 2021

BUY
$259.0 - $414.71 $67 Million - $107 Million
258,790 Added 321.44%
339,300 $117 Million
Q1 2021

May 17, 2021

BUY
$242.95 - $284.63 $17.2 Million - $20.2 Million
70,950 Added 742.15%
80,510 $22.5 Million
Q4 2020

Feb 16, 2021

BUY
$236.26 - $355.63 $2.26 Million - $3.4 Million
9,560 New
9,560 $2.34 Million
Q2 2020

Aug 14, 2020

SELL
$258.66 - $342.55 $12.4 Million - $16.4 Million
-48,002 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$268.85 - $341.04 $12.9 Million - $16.4 Million
48,002 New
48,002 $15.2 Million
Q4 2019

Feb 14, 2020

SELL
$220.06 - $304.07 $78.5 Million - $109 Million
-356,860 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$217.44 - $243.88 $77.6 Million - $87 Million
356,860 New
356,860 $83.1 Million
Q1 2019

May 15, 2019

SELL
$216.71 - $338.96 $14.5 Million - $22.6 Million
-66,780 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$278.5 - $352.75 $18.6 Million - $23.6 Million
66,780 New
66,780 $20.1 Million
Q4 2018

Feb 14, 2019

SELL
$278.5 - $352.75 $3.23 Million - $4.1 Million
-11,610 Closed
0 $0
Q3 2018

Nov 15, 2018

BUY
$293.51 - $383.83 $3.41 Million - $4.46 Million
11,610 New
11,610 $4.1 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $25B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Health Cor Management, L.P. Portfolio

Follow Health Cor Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Health Cor Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Health Cor Management, L.P. with notifications on news.